Aug 25 Regado Biosciences Inc said it
stopped enrollment in the late-stage trial for its lead drug
after an independent committee recommended raised serious
concerns of allergic reactions to the experimental blood
The drug, Revolixys, was being evaluated against the
anticoagulant bivalirudin in patients undergoing percutaneous
coronary intervention, which is performed to open blocked
coronary arteries and restore blood flow to the heart tissue.
Regado's shares crashed in July after it was revealed that a
data safety monitoring board was reviewing the heart trial data.
The U.S. Food and Drug Administration also imposed a
clinical hold on the trial.
(Reporting by Natalie Grover in Bangalore; Editing by Joyjeet